Introduction

In a decisive procedural outcome, the U.S. District Court for the Western District of Tennessee dismissed Solenis Technologies, LP’s patent infringement action against Buckman Laboratories, Inc. with prejudice — ending a 378-day litigation battle over glyoxalated vinylamide polymer technology. Filed on July 7, 2023, and closed on July 19, 2024, the case (No. 2:23-cv-02413) never reached trial, terminating at the pleading stage following Buckman’s successful Motion to Dismiss.

For IP professionals and patent litigators tracking specialty chemical patent infringement disputes, this outcome carries important lessons. A dismissal with prejudice signals not merely a procedural defeat, but a permanent bar — Solenis cannot refile these same claims in the same court. The case underscores how early-stage motion practice can be dispositive even in technically complex patent disputes involving polymer chemistry. R&D teams operating in the water treatment and paper processing chemical sectors should take note of both the patents at issue and the strategic implications of this result.

Case Overview

The Parties

The Patents at Issue

Solenis asserted three U.S. patents, all directed to **glyoxalation of vinylamide polymers** — a chemical process used to produce wet-strength and drainage-aid additives widely used in paper manufacturing:

• • US7,875,676 B2 (Application No. 11/895,923)
• • US8,222,343 B2 (Application No. 12/969,783)
• • US8,703,847 B2 (Application No. 13/524,741)

These patents collectively cover methods and compositions relating to glyoxalated polyacrylamide (GPAM) technology, a commercially significant category of paper-strength chemicals.

Litigation Timeline & Procedural History

Solenis filed suit in the Western District of Tennessee — a venue with natural strategic significance given that Buckman Laboratories is headquartered in Memphis. This eliminated any credible venue transfer argument and placed litigation in Buckman’s home jurisdiction, a notable plaintiff decision that may have carried strategic risks.

The case proceeded at the district court (first instance) level, never advancing beyond the motion to dismiss stage. Buckman filed its Motion to Dismiss on November 6, 2023 (ECF No. 25), accompanied by a supporting memorandum. The court ultimately granted that motion (ECF No. 56), closing the case within approximately 378 days of filing — a relatively swift resolution for patent litigation, which typically averages two to three years through trial.

No claim construction hearing, Markman proceedings, or summary judgment briefing appear to have been reached, indicating the dismissal was resolved on threshold legal grounds rather than technical patent merits.

The Verdict & Legal Analysis

Outcome

The Western District of Tennessee entered a Judgment by Court dismissing the entire action with prejudice pursuant to Defendants’ Motion to Dismiss. The formal judgment reads:

“IT IS THEREFORE ORDERED, ADJUDGED, AND DECREED that, in accordance with the Order Granting Motion to Dismiss, this action is DISMISSED WITH PREJUDICE.”

No damages award was issued. No injunctive relief was granted. The dismissal with prejudice represents a complete defense victory at the pleading stage.

Verdict Cause Analysis

The case was terminated on a Motion to Dismiss — a Rule 12(b) procedural mechanism — rather than on the merits of infringement, claim construction, or validity. While the specific legal grounds for dismissal are not detailed in the available case data, a successful Rule 12(b)(6) motion in patent litigation typically reflects one of several threshold failures:

• Failure to state a claim: Insufficient factual allegations establishing that the accused products practice the asserted patent claims
• Subject matter eligibility challenges (35 U.S.C. § 101): Increasingly, defendants challenge patent-eligible subject matter at the pleading stage, particularly in chemical process patents
• Pleading deficiencies: Inadequate specificity in mapping accused products to asserted claims under post-Iqbal/Twombly pleading standards

The dismissal with prejudice — rather than without prejudice — is particularly significant. Courts typically grant dismissal with prejudice only when amendment would be futile, when the plaintiff has had prior opportunity to cure deficiencies, or when the complaint’s deficiencies are incurable as a matter of law. This outcome suggests the court found fundamental defects in Solenis’s claims that could not be remedied through amended pleadings.

Legal Significance

This case illustrates a growing trend in patent litigation: early-stage motion practice as a case-dispositive strategy. For specialty chemical patents — including polymer process patents like those covering GPAM technology — defendants increasingly challenge infringement complaints at the Rule 12 stage before expensive discovery and claim construction proceedings begin.

The three asserted patents (US7,875,676; US8,222,343; US8,703,847) represent an interconnected patent family covering glyoxalated vinylamide polymers. A dismissal with prejudice on all three simultaneously suggests a systemic issue with Solenis’s complaint rather than patent-specific deficiencies.

Strategic Takeaways

For Patent Holders and Litigators:

• Complaint drafting in polymer chemistry cases demands granular claim-to-product mapping; conclusory infringement allegations are increasingly vulnerable at the Rule 12 stage
• Filing in a defendant’s home district eliminates venue challenges but may introduce local practice familiarity advantages for defense counsel
• Where multiple related patents are asserted, each patent’s claim mapping must independently satisfy pleading standards

For Accused Infringers:

• Early investment in Motion to Dismiss briefing can resolve multi-patent infringement actions before discovery costs escalate
• Retaining locally experienced defense counsel (as Buckman did with Baker Donelson’s Memphis office) provides procedural and relational advantages in home-district litigation

For R&D Teams:

• The survival of these three GPAM patents — dismissed on procedural rather than validity grounds — means US7,875,676 B2, US8,222,343 B2, and US8,703,847 B2 remain active and enforceable; freedom-to-operate (FTO) analyses in glyoxalated polymer technology should account for their continued validity

Industry & Competitive Implications

The Solenis v. Buckman dispute reflects intensifying IP competition in the specialty chemical sector, particularly within the pulp, paper, and water treatment chemical markets. GPAM-based wet-strength additives represent a high-value product category, and patent protection over glyoxalation processes is commercially significant for manufacturers defending market share.

Buckman’s successful defense — achieved without ever reaching technical merits — preserves its freedom to continue operating in the glyoxalated polymer space, at least relative to Solenis’s pleaded infringement theory. However, the dismissal with prejudice does not resolve the underlying question of whether Buckman’s products infringe these patents; it resolves only that this complaint failed to legally establish infringement.

For competitors operating in adjacent chemical process spaces, this case signals that asserting overlapping patent families in a single complaint requires rigorous pre-filing claim charts mapping each patent independently to specific accused products. Courts will not assume infringement across related patents merely because they share a technological subject matter.

Licensing professionals should note that the outcome does not establish a royalty-bearing license, design-around validation, or invalidity finding — leaving the competitive IP landscape between these two companies potentially unsettled.